Vivos Therapeutics, Inc. (VVOS)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 2
Do Nothing: the override gate failed (fundamentalScore 1 and qualitativeScore 1), avgDollarVolume20 is only 105597.59 USD versus the 5000000 USD floor, and the chart is only a weak bounce inside a broader downtrend.
Company overview
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing treatment alternatives for dentofacial abnormalities, obstructive sleep apnea, and snoring in adults. Its offerings include the Vivos System, a non-invasive treatment modality, and the VivoScore Program for screening and home sleep testing. The company primarily markets its products to general dentists in the United States and Canada.
Fundamental
very weakVivos Therapeutics faces severe liquidity and going-concern risks, with negative equity and high cash burn.
High-risk micro-cap with negative equity, very weak liquidity (current ratio ~0.27), major cash burn, and SEC-disclosed going-concern + Nasdaq delisting risk. Low EV/Sales is not enough to offset financing/dilution risk.
Sentiment
very weakSentiment is constrained by ongoing regulatory and financing uncertainties, including Nasdaq delisting risk.
Last-14d media coverage (aggregator-tier due to sparse primary coverage) is mixed around Q1 results—strong reported revenue growth, but worsening losses/cash burn dominate—while the 30–90d baseline is sparse (sentiment delta indeterminate). Retail/Reddit signal is empty and legal screens are clean, but a severe red-flag (going-concern/substantial doubt and Nasdaq listing-compliance overhang flagged upstream) caps the qualitativeScore at 1.
Technical
weakThe stock is experiencing a short-term rebound but remains in a broader downtrend with insufficient liquidity.
VVOS is in a very short-term bounce, not a healthy bullish trend. Price closed above EMA9, SMA20 and daily VWAP, but it remains below EMA21, SMA50 and SMA200, so the larger structure is still bearish. RSI14 has recovered to 43.5 from oversold conditions and MACD has crossed above its signal, yet MACD is still below zero and ADX14 at 25.76 suggests the broader trend remains strong rather than clearly reversed. The decisive technical problem is liquidity: avgDollarVolume20 is only 105597.59 USD, far below the 5000000 USD floor.
You’re looking at 2026-06-30 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.